Results 231 to 240 of about 16,542 (247)

Efficacy and Safety of Abrocitinib Versus Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomised, Double-Blind, Multicentre Phase 3 Trial

Lancet, The, 2022
Weily Soong, Urs Kerkmann, Ricardo Rojo
exaly  

Dupilumab Is Very Effective in a Large Cohort of Difficult-to-Treat Adult Atopic Dermatitis Patients: First Clinical and Biomarker Results From the BioDay Registry

Allergy: European Journal of Allergy and Clinical Immunology, 2020
Lieneke Fm Ariens, Edward Frank Knol, Femke van Wijk   +2 more
exaly  

Dupilumab-Induced Hypereosinophilia: Review of the Literature and Algorithm Proposal for Clinical Management

Expert Review of Respiratory Medicine, 2022
Marco Caminati, Claudio Micheletto, Pierluigi Paggiaro   +2 more
exaly  

Mechanisms of Dupilumab

Clinical and Experimental Allergy, 2020
Talal A Chatila, Hani Harb
exaly  

Dupilumab Suppresses Type 2 Inflammatory Biomarkers Across Multiple Atopic, Allergic Diseases

Clinical and Experimental Allergy, 2021
Gianluca Pirozzi, Jennifer D Hamilton, Allen Radin   +2 more
exaly  

Real-World Evidence of Dupilumab Efficacy and Risk of Adverse Events: A Systematic Review and Meta-Analysis

Journal of the American Academy of Dermatology, 2021
Nikolai Dyrberg Loft, Emma Guttman-Yassky, Anne-Sofie Halling   +2 more
exaly  

Dupilumab Use in Dermatologic Conditions Beyond Atopic Dermatitis – A Systematic Review

Journal of Dermatological Treatment, 2021
Vivian Y Shi, Aleksi J Hendricks
exaly  

Characterizing Dupilumab Facial Redness: A Multi-Institution Retrospective Medical Record Review

Journal of the American Academy of Dermatology, 2020
Jane M Grant-Kels, Brett Sloan, Reid A Waldman   +2 more
exaly  

Dupilumab’s duplicity

Journal of the American Academy of Dermatology
openaire   +2 more sources

Efficacy and Safety of Dupilumab in Patients With Severe Chronic Rhinosinusitis With Nasal Polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results From Two Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trials

Lancet, The, 2019
Gianluca Pirozzi, Tanya M Laidlaw, Peter W Hellings   +2 more
exaly